Group L. P. Column Acquires 50,000 Shares of NGM Biopharmaceuticals (NGM) Stock

NGM Biopharmaceuticals (NYSE:NGM) major shareholder Group L. P. Column purchased 50,000 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were purchased at an average cost of $13.50 per share, for a total transaction of $675,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of NYSE NGM traded down $0.09 during mid-day trading on Thursday, reaching $14.73. 611 shares of the company’s stock were exchanged, compared to its average volume of 110,491. NGM Biopharmaceuticals has a twelve month low of $12.00 and a twelve month high of $18.75.

A number of equities research analysts have recently commented on NGM shares. Citigroup started coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set a “buy” rating and a $29.00 price target on the stock. Goldman Sachs Group started coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set a “buy” rating and a $22.00 price target on the stock. Finally, Cowen started coverage on NGM Biopharmaceuticals in a research report on Monday, April 29th. They set an “outperform” rating and a $25.00 price target on the stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.com-unik.info/2019/05/23/group-l-p-column-acquires-50000-shares-of-ngm-biopharmaceuticals-ngm-stock.html.

About NGM Biopharmaceuticals

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.

Featured Article: Percentage Decliners

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit